Jasper Therapeutics, Inc.

JSPR · Nasdaq · United States

Share price · JSPR

$11.52-10.98 (-48.80%) 3M

close as of 2026-11-18 · 24h delayed · vol 19K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when JSPR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+11.4%

    Nothing announced by JSPR that day or the session before.

  2. 17 Nov 2026-12.1%
  3. 16 Nov 2026-14.0%
  4. 6 Nov 2026+19.8%

    Nothing announced by JSPR that day or the session before.

  5. 14 Jul 2026+18.9%

    Nothing announced by JSPR that day or the session before.

  6. 29 Jun 2026+23.1%
  7. 26 Jun 2026-23.0%
  8. 1 Jun 2026-35.6%
  9. 15 Apr 2026+12.6%

    Nothing announced by JSPR that day or the session before.

  10. 13 Apr 2026+14.5%

Share of unusual movement by asset

For each asset, the share of JSPR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
KITMonoclonal antibody
AsthmaChronic Spontaneous Urticaria

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 January 2026Topline resultBriquilimabUpdated BEACON and open label extension data for briquilimab in CSU

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$5.1M$7.7M$2.8M-$6.9M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$5.8M$15M$1.2M-$15M operating cash flowreport ↗
2025-Q3—$14M$51M$19M-$17M operating cash flowreport ↗
2025-Q2—$21M$40M$27M-$15M operating cash flowreport ↗
2025-Q1—$16M$49M$21M-$23M operating cash flowreport ↗
2024-Q3—$14M$93M$19M-$14M operating cash flowreport ↗
2024-Q2—$11M$107M$15M-$12M operating cash flowreport ↗
2024-Q1—$10M$119M$14M-$16M operating cash flowreport ↗
2023-Q3—$15M$104M+ $3.4M short-term inv.$18M-$12M operating cash flowreport ↗
2023-Q2—$13M$116M+ $3.2M short-term inv.$16M-$13M operating cash flowreport ↗
2023-Q1—$9.8M$130M$14M-$10M operating cash flowreport ↗
2022-Q3—$9.0M$51M$12M-$9.6M operating cash flowreport ↗
2022-Q2—$8.1M$61M$10M-$9.4M operating cash flowreport ↗
2022-Q1—$8.2M$71M$2.2M-$14M operating cash flowreport ↗
2021-Q3—$7.2M$101M$3.4M-$18M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$63M$29M$19M-$77M operating cash flowreport ↗

Jasper Therapeutics reported fiscal-year 2025 results, with research and development expense of $63.1M, up 13.0% YoY from $55.82M, and cash and cash equivalents of $28.7M at December 31, 2025. Revenue was not disclosed, and the company reported a net loss of $75.8M for the year.

The company stated it remains on track to commence patient enrollment in the Phase 2b portion of its planned Phase 2b/3 study in chronic spontaneous urticaria in the second half of 2026, pending capital availability. Clinical updates included positive BEACON study data, with 67% of additional patients in Cohort 9.1 achieving a complete response at 12 weeks and 75% of open-label extension participants achieving complete response or well-controlled disease, as well as positive preliminary ETESIAN asthma data. Jasper also announced the completion of an internal investigation into the anomalous July 2025 BEACON data, which found no issues with the drug product, and appointed Jeet Mahal as Chief Executive Officer.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$56M$72M$18M-$63M operating cash flowreport ↗
2023-FY—$52M$87M$16M-$52M operating cash flowreport ↗
2022-FY—$35M$39M$9.4M-$46M operating cash flowreport ↗
2021-FY—$25M$85M$7.7M-$34M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-31Shizuru Judith Anne · directorAward / grant (derivative)7,500——Form 4
2026-07-31EMSTER KURT VON · directorAward / grant (derivative)7,500——Form 4
2026-07-31Crutcher Patrick J · directorAward / grant (derivative)7,500——Form 4
2026-07-31Lucas Svetlana · directorAward / grant (derivative)7,500——Form 4
2026-07-31WIGGANS THOMAS G · directorAward / grant (derivative)7,500——Form 4
2026-07-20Ros Matthew E · Chief Operating OfficerOpen-market purchase (derivative)881——Form 4
2026-07-20Crutcher Patrick J · directorOpen-market purchase (derivative)888——Form 4
2026-07-16Crutcher Patrick J · directorAward / grant (derivative)15,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 58 reporting institutions held 15.8M shares ($13.8M, 47.5% of shares outstanding).

#InstitutionSharesValue
1Velan Capital Investment Management LP2,668,395$2.3M
2MILLENNIUM MANAGEMENT LLC1,617,531$1.4M
3ACORN CAPITAL ADVISORS, LLC1,411,492$1.2M
4KINGDON CAPITAL MANAGEMENT, L.L.C.1,352,106$1.2M
5MORGAN STANLEY1,333,420$1.2M
6VANGUARD CAPITAL MANAGEMENT LLC1,172,597$1.0M
7Rock Springs Capital Management LP1,100,726$964K
8Carlyle Group Inc.1,066,189$934K
9BOOTHBAY FUND MANAGEMENT, LLC582,751$511K
10Lion Point Capital, LP465,000$407K
11JACOBS LEVY EQUITY MANAGEMENT, INC322,273$282K
12GEODE CAPITAL MANAGEMENT, LLC317,677$278K
13BANK OF AMERICA CORP /DE/293,259$257K
14Soleus Capital Management, L.P.276,312$242K
15BlackRock, Inc.242,061$212K